EPHA2 and glioma: EphA2-directed CAR T cells have shown promising antiglioma activity in preclinical brain tumor models (53, 54), and at least one clinical trial is accruing patients with recurrent gliomas to evaluate the safety and efficacy of EphA2-CAR T cells (NCT03423992).